In autism, METTL3 stabilizes the expression of lncRNA MALAT1 by upregulating its m6A modification, which facilitates MALAT1 to recruit DNA methyltransferases DNMT1, DNMT3A, and DNMT3B to the promoter region of SFRP2, promoting SFRP2 methylation and reducing its expression, ultimately leading to Wnt/β-catenin signaling pathway inhibition, relieving hippocampal neuron apoptosis and autism-like symptoms [118]. Here, SFRP2 is linked to autism.